MT. KISCO, NY, — The Cancer Treatment and Wellness Center at Northern Westchester Hospital announced that its patients participating in international clinical cancer research studies conducted in partnership with the Mount Kisco Medical Group (MKMG) are playing an important role in the further development of IBRANCE® (palbociclib) capsules, a treatment developed and manufactured by Pfizer Inc.
The Cancer Treatment and Wellness Center (CTWC) at Northern Westchester Hospital (NWH) was one of the first sites in the world to make one of these studies available to patients.
Pfizer Inc. recently announced that the FDA approved IBRANCE® (palbociclib) capsules, the first-ever therapy targeting cyclin dependent kinases 4 and 6 (CDK4/6), for use in combination with letrozole to treat postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. To learn more about IBRANCE, and see the full prescribing information, please visit www.ibrance.com.
“The dedication and commitment of our patients and their willingness to participate in our palbociclib research trials continues to help evaluate this drug in other settings. This approval reinforces the importance of providing leading-edge care and access to investigational cancer drugs without having to travel outside of our community,” stated Jonathan Goldberg, MD, medical oncologist at the Mount Kisco Medical Group and medical director of Cancer Clinical Trials at NWH. “MKMG and NWH are honored to be playing a role in the development of this and other innovative cancer treatments. The joint MKMG and NWH clinical trials program, in addition to serving our local patient population, has now become a destination for cancer patients from outside our community looking to gain access to these promising research studies."
For more information on other clinical trials underway, please contact the NWH Clinical Trials Program by visiting www.nwhc.net/clinicaltrials or by calling 914.666.1366.
About the Mount Kisco Medical Group
The Mount Kisco Medical Group (MKMG) is a multi-specialty medical group that provides the highest quality medical care in 40 different locations throughout Westchester, Putnam, Dutchess, and Ulster counties. Founded in 1946, MKMG has grown to over 450 physicians representing 40 different medical specialties with major campuses in Mount Kisco, Carmel, Katonah, Kingston, Fishkill, Jefferson Valley, Poughkeepsie and Rhinebeck. MKMG is affiliated with world class organizations: the Massachusetts General Hospital, Mount Sinai Medical Center and Memorial Sloan Kettering Cancer Center. MKMG has on-site laboratory and radiology services, as well as endoscopy suites and infusion suites, rendering comprehensive care in one convenient location. MKMG physicians are frequently recognized as Best Doctors in respected publications: 63 of the 293 physicians featured in Westchester Magazine’s Top Doctors are MKMG doctors. Additionally, Best Doctors of America® awarded 79 MKMG physicians with Top Doctor Honors. Visit http://www.mkmg.com for more information.
About Northern Westchester Hospital
Northern Westchester Hospital (NWH), a member of the North Shore-LIJ Health System, provides quality, patient centered care that is close to home through a unique combination of medical expertise, leading edge technology, and a commitment to humanity. Over 700 highly skilled physicians, state-of-the-art technology and professional staff of caregivers are all in place to ensure that you and your family receive treatment in a caring, respectful and nurturing environment.
NWH has established extensive internal quality measurements that surpass the standards defined by the Centers for Medicare & Medicaid Services (CMS) and the Hospital Quality Alliance (HQA) National Hospital Quality Measures. Our high quality standards help to ensure that the treatment you receive at NWH is among the best in the nation. For more information, please visit www.nwhc.net and connect with us on Facebook.